Innovus Pharmaceuticals, Inc.

14 articles with Innovus Pharmaceuticals, Inc.

• Innovus Pharmaceuticals Reports Preliminary Q2 2018 Sales Revenue of $6.6 million to $6.8 million

  7/17/2018

  Preliminary Quarterly Revenue Increase of 47-51% and Comparable 2017 Second Quarter Increase of 330-340% and Fiscal Year 2018 Net Revenue Annual Guidance Adjusted Upwards to at Least $22 Million

• Innovus Pharmaceuticals, Inc.: Strong Growth in the OTC Personal Care Market -- SECFilings.com

  6/22/2018

  SECFilings.com announces the publication of an article covering Innovus Pharmaceuticals Inc. 

• Innovus Pharma Announces the Launch of Its Product AllerVarx™ in Canada for Allergic Rhinitis

  6/6/2018

  AllerVarx™ is the Ninth Innovus Pharma Product Launched in Canada to Date

• Innovus Pharma Announces the Approval of Its Product ProstaGorx™ in Canada for Benign Prostatic Hyperplasia (“BPH”)

  6/4/2018

  Innovus Pharmaceuticals, Inc. announced the approval by Health Canada of its product ProstaGorx™ as a Natural Health Product (NPN #80085717) for the relief of urologic symptoms.

• Innovus Pharma Chief Executive Officer to Present at 8th Annual LD Micro Invitational Conference

  5/31/2018

  Innovus Pharmaceuticals, Inc. announced that Dr. Bassam Damaj, its President and Chief Executive Officer, will speak at the 8th Annual LD Micro Invitational Conference.

• Innovus Pharmaceuticals to Release Its First Quarter 2018 Financial Results on Monday, May 14, 2018

  5/4/2018

  Innovus Pharmaceuticals, Inc. announced that the Company will release its March 31, 2018 first quarter financial results on Monday, May 14, 2018.

• Innovus Pharma Announces the Launch of its Hemorrhoid Drug Xyralid® in Canada

  4/26/2018

  Xyralid®, a Lidocaine-based Cream for the Relief of Pain and Symptoms Caused by Hemorrhoids, is the Sixth Innovus Pharma Product launched in Canada to Date

• Innovus Pharma Expands its Senior Management with the Addition of Ryan Selhorn, CPA, as its Vice President, Chief Financial Officer

  4/23/2018

  Industry Veteran to Lead Company’s Financial and Accounting Operations into its Expanding Revenue Growth Stage

• Innovus Pharma Announces U.S. Food and Drug Administration Clearance of its GlucoGorx™ Glucose Monitoring Device Test Kit

  4/12/2018

  Innovus Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has cleared the Company’s GlucoGorx™ Glucose Monitoring Test Kit that includes a glucose meter, test strips and lancet device (“GlucoGorx™ Kit”) under the 510(k) filing of its manufacturing partner, ACON Laboratories, Inc. (“ACON”) Innovus Pharma will offer the GlucoGorx™ Kit.

• Acerus Announces Launch of URIVARX® in Canada

  4/9/2018

  Acerus had previously planned for the Canadian launch of URIVARX® in the second half of 2018, but the Company has arranged for the product to be available in Canada via the Innovus supply chain.

• Innovus Pharmaceuticals Reports Record Annual Revenue for Fiscal 2017 of $8.8 Million, Preliminary Q1 2018 Revenue of $4.3 Million to $4.4 Million and Expects to Exit 2018 Profitable

  4/2/2018

  Year over Year Revenue Increase of 83% with Reduction in Net Loss of 53% in 2017 and Fiscal Year 2018 Net Revenue Annual Run Rate of At Least $18 million

• Innovus Pharma’s AllerVarx™ Receives Commercial Approval by Health Canada for the Reduction in Symptoms of Seasonal Allergic Rhinitis

  2/28/2018

  AllerVarx™ is the Eighth Innovus Pharma Product approved in Canada to date

• Innovus Pharma Launches its New Brand, Logo and its Latest E-Commerce-Enhanced Content Website

  2/27/2018

  New Website Features its Robust Beyond Human® Sales & Marketing Platform

• Innovus Pharma Announces the Complete Repayment in Cash of its Financial Obligations from its Acquisition of its Beyond Human® Assets

  2/22/2018

  Payoff in Cash of Outstanding Secured Promissory Note with SBI Investments, LLC also Releases Lien on Company’s Beyond Human® Assets and the Related Revenues